Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Therapeutic or Preventive Procedure > AT protocol

AT protocol

AT protocol: A standardized procedure or set of guidelines for the assessment, selection, and implementation of assistive technologies (AT) to address the needs of individuals with disabilities or functional limitations.
AT protocols aim to ensure the appropriate and effective use of AT devices and services, optimizing outcomes and promoting independence.
These protocols may cover areas such as device evaluation, user assessment, training, and ongoing support.
Adherence to established AT protocols can help healthcare professionals, educators, and caregivers make informed decisions and provide personalized AT solutions that enhance the quality of life for those requiring assistive technologies.
Explore the latest AT protocols through published literature, preprints, and patents using PubCompare.ai's revolutionary AI-powered platform, which enables easy location, comparison, and selection of the most effective protocols to meet your clients' needs.

Most cited protocols related to «AT protocol»

1
Fluorescent Probe Preparation and Hybridization
Cited 36 times
10 μg of total RNA were used to prepare probes. Labeling was performed with the Invitrogen SuperScript™ Indirect cDNA labeling system (using polyA and random hexamers primers) using the Amersham Cy3 or Cy5 monofunctional reactive dyes. Probe quality was assessed on an agarose minigel and quantified with a Nanodrop ND-1000 spectrophotometer. Dye quantities were equilibrated for hybridization by the amount of fluorescence per ng of cDNA. The arrays were hybridized for 20 h at 45°C according to the manufacturers protocol (QMT ref). Washing was performed in 2× SSC 0.1% SDS at 42°C for 5' and then twice at room temperature in 1× SSC, 0.5× SSC each time for 5'. Arrays were scanned using a GenePix Axon scanner.
Fierro A.C., Thuret R., Engelen K., Bernot G., Marchal K, & Pollet N. (2008). Evaluation of time profile reconstruction from complex two-color microarray designs. BMC Bioinformatics, 9, 1.
Full text: Click here
Publication 2008
Acid Hybridizations, Nucleic AT protocol Axon DNA, Complementary Fluorescence Oligonucleotide Primers Poly A Sepharose
2
Amplification and Sequencing of 16S rRNA Genes
Cited 30 times
We used primers previously designed to amplify the V4-V5 hyper-variable regions of the 16S rRNA gene to generate the 454 and Illumina libraries using fusion primer designs appropriate for the respective sequencing platforms (Table 1) [28] (link). The 16S template binding sequence was identical between both sets of fusion primers, with the 454 fusion primers following the standard format used by the Marine Biological Laboratory (MBL) and the Illumina fusion primers using the format described by Bartram et al. [17] (link). Libraries for all seven samples were prepared and sequenced by 454 pyrosequencing at the MBL's Josephine Bay Paul Center according to their standard protocols on a GS FLX using Titanium sequencing chemistry [28] (link).
The Illumina sequencing libraries were all prepared and sequenced at the University of Connecticut. We prepared two sets of V4-V5 Illumina libraries for the six natural community samples at two separate times. The first set of libraries was prepared following the same protocol used for the 454 pyrosequencing libraries, with the PCR product for each sample gel purified prior to pooling and sequencing. The PCR products for the second set of V4-V5 Illumina libraries and the mock community libraries were purified using a 0.6X PCR volume of AMPure XP magnetic beads following the manufacturer's instructions. Additionally, we prepared libraries for the V4 hyper-variable region according to the protocol described by Caporaso et al. [18] (link). The Illumina libraries were sequenced on separate runs of a MiSeq using a 2×250 bp paired end protocol.
Nelson M.C., Morrison H.G., Benjamino J., Grim S.L, & Graf J. (2014). Analysis, Optimization and Verification of Illumina-Generated 16S rRNA Gene Amplicon Surveys. PLoS ONE, 9(4), e94249.
Full text: Click here
Publication 2014
AT protocol Biopharmaceuticals Marines Oligonucleotide Primers Ribosomal RNA Genes Titanium
3
Comparing HIV Antiretroviral Regimens
Cited 19 times
The AIDS Clinical Trials Group Study A5202 is an ongoing phase 3B, randomized, partially blinded study comparing four antiretroviral regimens for the initial treatment of HIV-1 infection. The planned study duration was 96 weeks after enrollment of the last patient. Baseline evaluations included a medical history, physical examination, CD4 cell count, and HIV-1 RNA level. At screening, a genotypic resistance test was required in patients with recent HIV-1 acquisition. Testing for the HLA-B*5701 allele was permitted but not required. Patients were randomly assigned to receive one of four oral once-daily regimens: 600 mg of efavirenz (Sustiva, Bristol-Myers Squibb) or 300 mg of atazanavir (Reyataz, Bristol-Myers Squibb) plus 100 mg of ritonavir (Norvir, Abbott Laboratories) given with either 600 mg of abacavir plus 300 mg of lamivudine (Epzicom, GlaxoSmithKline) or 300 mg of tenofovir DF plus 200 mg of emtricitabine (Truvada, Gilead Sciences). The study was double-blinded with regard to the NRTIs.
Randomization was stratified according to the screening HIV-1 RNA level obtained before study entry (≥100,000 vs. <100,000 copies per milliliter), with the use of a permuted-block design with dynamic balancing according to the main institution. Screening of HIV-1 RNA levels was performed at any laboratory certified under the Clinical Laboratory Improvement Amendments. Study evaluations were completed before entry, at entry, at weeks 4, 8, 16, and 24, and every 12 weeks thereafter for the duration of the study in all patients, regardless of any treatment modification. After screening, the level of HIV-1 RNA was measured (Roche Amplicor Monitor assay, version 1.5) at Johns Hopkins University. At the time of protocol-defined virologic failure, geno-typing for drug resistance was performed at Stanford University; the baseline samples obtained from the patients were genotyped retrospectively.
Abbott Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, and GlaxoSmithKline provided the study medications and had input into the protocol development and review of the manuscript. All the authors participated in the trial design, data analysis, and preparation of the manuscript, and all the authors vouch for the completeness and accuracy of the reported data.
Sax P.E., Tierney C., Collier A.C., Fischl M.A., Mollan K., Peeples L., Godfrey C., Jahed N.C., Myers L., Katzenstein D., Farajallah A., Rooney J.F., Ha B., Woodward W.C., Koletar S.L., Johnson V.A., Geiseler P.J, & Daar E.S. (2009). Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy. The New England journal of medicine, 361(23), 2230-2240.
Publication 2009
abacavir - lamivudine Acquired Immunodeficiency Syndrome Alleles Atazanavir AT protocol Biological Assay CD4+ Cell Counts Clinical Laboratory Services efavirenz Emtricitabine Epzicom HIV-1 HIV Infections Norvir Patients Pharmaceutical Preparations Physical Examination Resistance, Drug Reyataz Ritonavir Sustiva Tenofovir Disoproxil Fumarate Testing, AIDS Treatment Protocols Truvada
4
Optimized Hi-C Data Analysis Protocol
Cited 18 times
In the following, we analyzed separately each different experiment conducted in
[13 (link)] since different protocols can produce different results. Notably, the use of the secondary enzyme (MspI or MseI) change the potential interactions that can be observed.
Only the reads exhibiting a position on the genome reconcilable with the protocol design were retained (Figure
1A). Firstly, they are expected to map at a distance of about 20 bp to the nearest Hind III restriction site due to the use of the enzyme Ecop15I at the step 10 of the protocol (Figure
1A). We computed the number of read pairs as a function of the distance between the beginning of the read to the next RE1 site for each experiment. We found little difference between condition A and condition B (conditions A and B differ in the DNA concentration at the 3C step: A: 0.5 μg/ml , B: 0.3 μg/ml ). Whereas reads from datasets HindIII-MspI-A and HindIII-MseI-A have maximums for distances equals to 20, 21 and 22 bp, HindIII-MspI-B, HindIII-MseI-B and HindIII-MseI-uncross-control-B exhibit maximums for distances equals to 21, 22 and 23 bp (see Additional file
1: Figure S11). We only kept reads with distance between the beginning of the read and the next RE1 site equal to 20, 21 and 22 bp for condition A and equals to 21, 22 and 23 bp for condition B. Secondly, interactions involving fragments which have no restriction site for the secondary enzyme or a secondary site with a position located less than 20 bp from the first restriction site were also discarded. Finally, interactions corresponding to self-circularization (loops) and ligation of adjacent fragments (religation events) were removed from the analysis.
Cournac A., Marie-Nelly H., Marbouty M., Koszul R, & Mozziconacci J. (2012). Normalization of a chromosomal contact map. BMC Genomics, 13, 436.
Full text: Click here
Publication 2012
AT protocol DNA Restriction Enzymes Enzymes Genome Ligation
5
Alternative Synthesis Methods for Systematic Reviews
Cited 17 times
Around a third to half of all systematic reviews do not use meta-analysis at all,23 (link),24 (link) and more do not use meta-analysis for all outcomes. Reasons why meta-analysis may not be possible are varied, but one reason may be when the included primary studies do not provide the necessary data required for a meta-analysis. For example, the studies may report statements about the direction of effect without an effect estimate, or report effect estimates without measures of variance.
For the first time, Chapter 12 of the Handbook presents a number of alternative statistical synthesis methods for this scenario, including the use of summary statistics to describe the observed range of intervention effect estimates, vote counting based on the direction of effect, or combining P values. Companion visual displays for these synthesis methods are also described, including box plots, harvest plots and albatross plots.
In some cases, synthesis may be inappropriate, for example where the included studies are at a high risk of bias or there are concerns about missing evidence. In such cases, structured tabulation or plotting the results without synthesis may be used for presentation.25
Although these alternative synthesis methods yield results that are more limited for decision making in comparison to meta-analysis, they provide additional options for review authors when the required data for meta-analysis are not available. These methods may enable authors to make the most of the available data and provide a structured approach where authors may have felt limited to text-based descriptions of the findings of individual studies, which can become rapidly unwieldy where large numbers of studies or complex interventions are involved. The recently updated PRISMA26 (link) and Synthesis Without Meta-analysis (SWiM)27 reporting guidelines may be of additional assistance to authors unsure of how to specify the use of these methods at the protocol stage of the review, and how to completely report which methods have been used in practice.
Cumpston M.S., McKenzie J.E., Welch V.A, & Brennan S.E. (2022). Strengthening systematic reviews in public health: guidance in the Cochrane Handbook for Systematic Reviews of Interventions, 2nd edition. Journal of Public Health (Oxford, England), 44(4), e588-e592.
Publication 2022
Anabolism AT protocol Feelings Pets

Most recents protocols related to «AT protocol»

1
Dandelion Root Intake and Anesthesia
Every morning for four weeks, the animals received fresh dandelion root in a 250 ml volume bottle [6 (link)]. In order to accurately record the intake of dandelion root, each animal was placed in a separate cage, while the volume of tea was recorded daily. The average daily dandelion root intake was 39.44 ± 2.67 ml in the experimental group, while the control group took tap water in an average amount of 42.85 ± 3.16 ml.
The animals were subjected to anesthesia at the end of the experimental protocol prior to sacrifice. A mixture of ketamine (Vet-Agro, Lublin, Poland) and xylazine (De Adelaar B.V, Venray, Holland) was prepared in a syringe. Administration of 25 µl/kg ketamine and 62.5 µl/kg xylazine was equivalent to the recommended dosage of 10 mg ketamine/kg and 5 mg xylazine/kg for rats [11 (link)]. The ketamine/xylazine mixture was administered i.p., and after 2 min, animals were sacrificed by decapitation.
Radoman K., Zivkovic V., Zdravkovic N., Chichkova N.V., Bolevich S, & Jakovljevic V. (2023). Effects of dandelion root on rat heart function and oxidative status. BMC Complementary Medicine and Therapies, 23, 78.
Full text: Click here
Publication 2023
Anesthesia Animals AT protocol Decapitation Ketamine Plant Roots Rattus norvegicus Syringes Taraxacum Xylazine
2
Dandelion Root Effects on Wistar Rats
The study was carried out on 20 male Wistar albino rats (8 weeks old, body weight 250 ± 20 g). The animals consumed commercial rat food (20% protein rat food, Veterinary Institute Subotica, Serbia) and were housed under controlled environmental conditions at room temperature (22 ± 1 °C) with a 12-h light/day photoperiod. The rats had free access to food and tap water ad libitum. At the beginning of the experimental protocol, rats were randomly classified into two groups (10 rats per group):

Control group – animals that drank tap water.

Experimental group – animals that drank dandelion root for four weeks [6 (link)].

Radoman K., Zivkovic V., Zdravkovic N., Chichkova N.V., Bolevich S, & Jakovljevic V. (2023). Effects of dandelion root on rat heart function and oxidative status. BMC Complementary Medicine and Therapies, 23, 78.
Full text: Click here
Publication 2023
Albinism Animals Animals, Laboratory AT protocol Body Weight Food Light Males Plant Roots Proteins Rats, Wistar Rattus norvegicus Taraxacum
3
Phosphorylation and Isolation of AGO-miRNA/RNA Complexes

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
AT protocol Bistris Buffers Centrifugation Chloroform Cold Temperature Edetic Acid Endopeptidase K Ethanol hydroxybenzoic acid Isopropyl Alcohol MicroRNAs Nitrocellulose Phosphorylation polyacrylamide gels Polynucleotide 5'-Hydroxyl-Kinase Radioactivity Reducing Agents SDS-PAGE Sodium Chloride Tissue, Membrane Tromethamine Urea
4
SARS-CoV-2 Antibody Isotype Quantification
Blood samples were transported from the field to the biobank in the University of Navarra by cold chain using coolers. At the end of each day, blood was centrifuged, and the plasma separated and kept at -80ºC in the laboratory until the shipment to ISGlobal for serological analysis.
We measured the levels of three antibody isotypes (IgG, IgM and IgA) against the SARS-CoV-2 S glycoprotein, produced at the Centre de Regulació Genòmica (CRG), and RBD, kindly donated by the Krammer lab (Mount Sinai, New York)17 (link) using a previously validated method based on quantitative suspension array technology (xMAP®, Luminex®)18 (link). This method, using IgG, IgM and IgA isotypes and RBD and S antigens yielded a sensitivity of 83% and a specificity of 95%19 .
Plasma samples were incubated with MagPlex® Microspheres coated with the S and RBD antigens. After wash, beads were incubated with anti-human Ig labelled with fluorescent phycoerythrin and resuspended with an assay buffer and read in a Luminex® 100/200 equipment for quantification of bound IgG, IgM and IgA. Levels of antibodies were expressed in median fluorescence intensity (MFI). Seropositivity was determined based on a threshold calculated as 10 to the mean plus 3 standard deviations of log10-transformed MFIs of 71 negative controls (pre-pandemic samples from adults ranging 20–60 years of age). All methods were carried out in accordance with relevant guidelines and regulations20 .
At the time of protocol development, the S antigen from the Wuhan strain was chosen because it was the leading vaccine candidate target and one of the most immunogenic. RBD—the fragment of S protein that mediates binding of the virus to the host receptor ACE2 in the lung cells—was also analyzed because IgG levels to RBD correlated with the levels of neutralizing antibodies that had been associated with protection21 .
Ribes M., Montañà J., Vidal M., Aguilar R., Nicolás P., Alfonso U., Rodrigo N., Carolis C., Dobaño C., Moncunill G, & Chaccour C. (2023). Seroprevalence and socioeconomic impact of the first SARS-CoV-2 infection wave in a small town in Navarre, Spain. Scientific Reports, 13, 3862.
Full text: Click here
Publication 2023
ACE2 protein, human Adult Antibodies Antibodies, Neutralizing Antigens AT protocol Biological Assay BLOOD Buffers Cells Fluorescence Glycoproteins Homo sapiens Hypersensitivity Immunoglobulin Isotypes Lung Microspheres Pandemics Phycoerythrin Plasma SARS-CoV-2 spike protein, SARS-CoV-2 Strains Vaccines
5
Comprehensive Soil Microbiome Analysis via 16S rRNA Sequencing
Total genomic DNA was extracted from all the 192 samples, i.e., bulk soils (0.25 g), rhizospheres (approximately 0.25 g), and smashed roots, using the DNeasy PowerSoil Kit (QIAGEN, Hilden, Germany) following the manufacturer’s instructions with minor modifications: a FastPrep instrument (MP Biomedicals, Irvine, CA, United States) was used for the homogenization step with a cycle consisting of three 1-min steps at 5.5 movements per sec with 5-min incubations in ice between each run and, at the end of the protocol, DNA elution was preceded by a 5-min incubation in ice. Then, DNA was quantified by using NanoDrop ND1000 (NanoDrop Technologies, Wilmington, DE) and diluted in PCR grade water to the final concentration of 5 ng/μl before amplification. Five microliters of diluted DNA were used as template for the PCR reaction. PCR was performed in a final volume of 50 μl containing 25 ng of genomic DNA, 2X KAPA HiFi HotStart ReadyMix (Roche, Basel, Switzerland) and 200 nmol/L of 341F and 785R primers carrying Illumina overhang adapter sequences for amplification of the V3–V4 hypervariable regions of the 16S rRNA gene. Specifically, the thermal cycle consisted of initial denaturation at 95°C for 3 min followed by 25 cycles of denaturation (95°C for 30 s), annealing (55°C for 30 s), and extension (72°C for 30 s), with a final extension step at 72°C for 5 min (Turroni et al., 2016 (link)). PCR amplicons were cleaned up with Agencourt AMPure XP magnetic beads (Beckman Coulter, Brea, CA, United States). Indexed libraries were prepared by limited-cycle PCR using Nextera technology. Indexing was followed by a second clean-up step, as already described, and then libraries were quantified using Qubit 3.0 fluorimeter (Invitrogen), normalized to 4 nM and pooled. Before sequencing, the sample pool was denatured with 0.2 N NaOH and diluted to 4.5 pM with a 20% PhiX control. Sequencing was performed on Illumina MiSeq platform using a 2 × 250 bp paired end protocol, according to the manufacturer’s instructions (Illumina, San Diego, CA, United States). Sequencing reads were deposited in the ENA archive with the accession code PRJEB57815.
Nanetti E., Palladino G., Scicchitano D., Trapella G., Cinti N., Fabbrini M., Cozzi A., Accetta G., Tassini C., Iannaccone L., Candela M, & Rampelli S. (2023). Composition and biodiversity of soil and root-associated microbiome in Vitis vinifera cultivar Lambrusco distinguish the microbial terroir of the Lambrusco DOC protected designation of origin area on a local scale. Frontiers in Microbiology, 14, 1108036.
Full text: Click here
Publication 2023
AT protocol Dietary Fiber Gene Amplification Genome Movement Oligonucleotide Primers Plant Roots Rhizosphere RNA, Ribosomal, 16S

Top products related to «AT protocol»

1
Lipofectamine 2000 by Thermo Fisher Scientific
Sourced in United States, China, Germany, United Kingdom, Canada, Japan, France, Italy, Switzerland, Australia, Spain, Belgium, Denmark, Singapore, India, Netherlands, Sweden, New Zealand, Portugal, Poland, Lithuania, Hong Kong, Argentina, Ireland, Austria, Israel, Czechia, Cameroon, Taiwan, Province of China, Morocco
Lipofectamine 2000 is a cationic lipid-based transfection reagent designed for efficient and reliable delivery of nucleic acids, such as plasmid DNA and small interfering RNA (siRNA), into a wide range of eukaryotic cell types. It facilitates the formation of complexes between the nucleic acid and the lipid components, which can then be introduced into cells to enable gene expression or gene silencing studies.
2
Rneasy mini kit by Qiagen
Sourced in Germany, United States, United Kingdom, Netherlands, Spain, Japan, Canada, France, China, Australia, Italy, Switzerland, Sweden, Belgium, Denmark, India, Jamaica, Singapore, Poland, Lithuania, Brazil, New Zealand, Austria, Hong Kong, Portugal, Romania, Cameroon, Norway
The RNeasy Mini Kit is a laboratory equipment designed for the purification of total RNA from a variety of sample types, including animal cells, tissues, and other biological materials. The kit utilizes a silica-based membrane technology to selectively bind and isolate RNA molecules, allowing for efficient extraction and recovery of high-quality RNA.
3
C57bl 6j mice by Jackson ImmunoResearch
Sourced in United States, Montenegro, Japan, Canada, United Kingdom, Germany, Macao, Switzerland, China
C57BL/6J mice are a widely used inbred mouse strain. They are a commonly used model organism in biomedical research.
4
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
5
C57bl 6j by Jackson ImmunoResearch
Sourced in United States, Montenegro, Germany, United Kingdom, Japan, China, Canada, Australia, France, Colombia, Netherlands, Spain
C57BL/6J is a mouse strain commonly used in biomedical research. It is a common inbred mouse strain that has been extensively characterized.
6
C57bl 6 by Jackson ImmunoResearch
Sourced in United States, Montenegro, United Kingdom, Germany, Australia, China, Canada
C57BL/6 is a widely used inbred mouse strain. It is a robust, readily available laboratory mouse model.
7
Trizol reagent by Thermo Fisher Scientific
Sourced in United States, China, Japan, Germany, United Kingdom, Canada, France, Italy, Australia, Spain, Switzerland, Netherlands, Belgium, Lithuania, Denmark, Singapore, New Zealand, India, Brazil, Argentina, Sweden, Norway, Austria, Poland, Finland, Israel, Hong Kong, Cameroon, Sao Tome and Principe, Macao, Taiwan, Province of China, Thailand
TRIzol reagent is a monophasic solution of phenol, guanidine isothiocyanate, and other proprietary components designed for the isolation of total RNA, DNA, and proteins from a variety of biological samples. The reagent maintains the integrity of the RNA while disrupting cells and dissolving cell components.
8
Lipofectamine 3000 by Thermo Fisher Scientific
Sourced in United States, China, Germany, Japan, United Kingdom, France, Canada, Italy, Australia, Switzerland, Denmark, Spain, Singapore, Belgium, Lithuania, Israel, Sweden, Austria, Moldova, Republic of, Greece, Azerbaijan, Finland
Lipofectamine 3000 is a transfection reagent used for the efficient delivery of nucleic acids, such as plasmid DNA, siRNA, and mRNA, into a variety of mammalian cell types. It facilitates the entry of these molecules into the cells, enabling their expression or silencing.
9
Miseq platform by Illumina
Sourced in United States, China, Germany, United Kingdom, Spain, Australia, Italy, Canada, Switzerland, France, Cameroon, India, Japan, Belgium, Ireland, Israel, Norway, Finland, Netherlands, Sweden, Singapore, Portugal, Poland, Czechia, Hong Kong, Brazil
The MiSeq platform is a benchtop sequencing system designed for targeted, amplicon-based sequencing applications. The system uses Illumina's proprietary sequencing-by-synthesis technology to generate sequencing data. The MiSeq platform is capable of generating up to 15 gigabases of sequencing data per run.
10
C57bl 6 mice by Jackson ImmunoResearch
Sourced in United States, Montenegro, Canada, China, France, United Kingdom, Japan, Germany
C57BL/6 mice are a widely used inbred mouse strain commonly used in biomedical research. They are known for their black coat color and are a popular model organism due to their well-characterized genetic and physiological traits.

More about "AT protocol"

Assistive Technology (AT) Protocols: Enhancing Accessibility and Independence Assistive Technology (AT) protocols are standardized procedures and guidelines designed to ensure the appropriate and effective use of AT devices and services.
These protocols cover various aspects, including device evaluation, user assessment, training, and ongoing support.
By adhering to established AT protocols, healthcare professionals, educators, and caregivers can make informed decisions and provide personalized AT solutions that enhance the quality of life for individuals with disabilities or functional limitations.
The development and implementation of AT protocols often involve the use of specialized tools and techniques.
For example, the Lipofectamine 2000 and Lipofectamine 3000 transfection reagents are commonly used in the assessment and testing of AT devices.
Additionally, the RNeasy Mini Kit and TRIzol reagent may be utilized in the analysis of user feedback and preferences.
The C57BL/6J and C57BL/6 mouse strains, which are widely used in biomedical research, can also provide insights into the effectiveness and user-friendliness of AT solutions.
The latest AT protocols can be explored through published literature, preprints, and patents using advanced platforms like PubCompare.ai.
This revolutionary AI-powered platform enables easy location, comparison, and selection of the most effective AT protocols to meet the specific needs of clients.
By leveraging the power of the MiSeq platform and other cutting-edge technologies, PubCompare.ai can provide healthcare professionals, educators, and caregivers with the tools they need to make informed decisions and deliver optimal AT solutions.
Incorporating AT protocols into the assessment, selection, and implementation of assistive technologies can help enhance the independence, functionality, and overall quality of life for individuals requiring these essential aids.
Whether you're a healthcare provider, an educator, or a caregiver, staying up-to-date with the latest AT protocols and utilizing the right tools and techniques can make a significant difference in the lives of those you serve.